Epigenetic alterations which could potentially be used as biomarkers were also described for other cardiovascular diseases, e.g., methylated DNA of CD4 + cells in pulmonary arterial hypertension or DNA methylation profile of human leukocyte antigen-G in CAD [46, 47]. This evidence concerns the gene CD4 and coronary artery disorder.